[
  {
    "ts": null,
    "headline": "This Medicare premium just crossed $200 a month for the first time. Here’s why.",
    "summary": "The 9.7% increase in the cost of Medicare Part B premiums for 2026 is due to several factors, including projected growth in Medicare Advantage and outpatient care next year",
    "url": "https://finnhub.io/api/news?id=a1d5166854a31e6f345a84b662afd9d2c76ddf9932667fb7f7afb3743ab85145",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763818200,
      "headline": "This Medicare premium just crossed $200 a month for the first time. Here’s why.",
      "id": 137586794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The 9.7% increase in the cost of Medicare Part B premiums for 2026 is due to several factors, including projected growth in Medicare Advantage and outpatient care next year",
      "url": "https://finnhub.io/api/news?id=a1d5166854a31e6f345a84b662afd9d2c76ddf9932667fb7f7afb3743ab85145"
    }
  },
  {
    "ts": null,
    "headline": "Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success?",
    "summary": "Curious if Regeneron Pharmaceuticals is actually worth its current price tag? You are not alone; investors across the board are wondering whether now is the right time to add it to their portfolios. Shares have jumped 29.3% over the past month, including a 9.0% rise in just the last week. This has definitely caught the market’s attention and may signal shifting expectations on growth or risk. Recent headlines have highlighted promising clinical trial updates and new drug approvals. Both of...",
    "url": "https://finnhub.io/api/news?id=d53514874776b21cf6f0938ea863d0adfb4feab0087b75c7ea44cb3bb0e53cbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763806159,
      "headline": "Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success?",
      "id": 137579022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Curious if Regeneron Pharmaceuticals is actually worth its current price tag? You are not alone; investors across the board are wondering whether now is the right time to add it to their portfolios. Shares have jumped 29.3% over the past month, including a 9.0% rise in just the last week. This has definitely caught the market’s attention and may signal shifting expectations on growth or risk. Recent headlines have highlighted promising clinical trial updates and new drug approvals. Both of...",
      "url": "https://finnhub.io/api/news?id=d53514874776b21cf6f0938ea863d0adfb4feab0087b75c7ea44cb3bb0e53cbb"
    }
  }
]